Boston Scientific Invests $1.5B in MiRus, Secures Option to Acquire TAVR System
Advertisement
Under the agreement, Boston Scientific will have the right to acquire full ownership of MiRus’ TAVR business for additional aggregate payments of up to $3 billion, subject to milestones and further terms.
Boston Scientific has invested $1.5 billion in private medtech company MiRus, securing a 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement (TAVR) system, according to a statement issued May 19.
Under the agreement, Boston Scientific will have the right to acquire full ownership of MiRus’ TAVR business for additional aggregate payments of up to $3 billion, subject to milestones and further terms. The deal positions the company to potentially expand into next-generation structural heart therapies.
MiRus is developing the SIEGEL Balloon Expandable TAVR system, an investigational device designed to be approximately half the size of currently available delivery sheaths used in transcatheter aortic valve replacement procedures. The reduced size is intended to lower the risk of vascular complications and improve procedural outcomes.
TAVR is a minimally invasive procedure used to replace a narrowed aortic valve without open-heart surgery, typically performed through a catheter inserted via a small incision in an artery.
The investment comes after Boston Scientific previously withdrew its own transcatheter aortic valve platforms, including Acurate neo2 and Acurate Prime, from global markets following clinical setbacks. The company also stated it would not pursue U.S. approval for those systems.
The new agreement provides Boston Scientific a pathway back into the TAVR space through MiRus’ technology, should it exercise its acquisition option in the future.
MiRus founder and CEO Jay Yadav said the collaboration could accelerate development of the SIEGEL valve, highlighting its nickel-free structure, precise placement characteristics, and favorable hemodynamic profile as key design advantages.
Boston Scientific has been actively expanding its medtech portfolio in 2026. Earlier this year, the company completed a $14.5 billion acquisition of Penumbra, strengthening its thrombectomy and vascular intervention capabilities. It also acquired Valencia Technologies in an earlier undisclosed deal.
Stay tuned for more such updates on Digital Health News
